[Guangzhou, China, November 17, 2022]

Recently, Guangzhou AIChemEco Technology Co., LTD. (hereinafter referred to as "AIChemEco") and Chengdu Lead Drug Development Co., LTD. (Shanghai Stock Exchange stock code: 688222.SH, hereinafter referred to as "Chengdu Lead") signed the relevant agreement on scientific and technological cooperation of the New drug research and development technology platform, and the two parties will carry out in-depth cooperation in the development and application of automated high-throughput synthesis technology, project acceptance and delivery, and design and construction of new compound library.

The conclusion of this cooperation marks the further improvement of Chengdu Lead's forward-looking layout in the field of automated high-throughput synthesis technology, and also fully reflects the technical characteristics of Standard Wisdom in automated high-throughput chemical synthesis in the future. Based on the open innovation concept and complementary advantages,AIChemEco and Chengdu Lead will jointly promote automated high-throughput chemical synthesis technology and drug molecule discovery platform and application in drug research and development.

Chemical synthesis is the main method for human to make compounds, and it is also one of the main ways to synthesize drug molecules. For a long time, chemical synthesis has been highly dependent on manual trial and error by high-level talents, and the resulting uncertainty in the delivery of compounds is a traditional problem faced by the chemical synthesis industry. With the development and application of automation and artificial intelligence technology in the field of life science, the automation and intelligence of chemical synthesis have gradually been recognized by chemists all over the world.

We have a world-class high-throughput chemical synthesis technology team, independently designed and built the world's leading ultra-high throughput automatic synthesis platform, which can not only achieve the standardized operation of most reactions and experiments, but also achieve ultra-high experimental throughput, and the platform capacity has exceeded 10,000 experiments per day. Relying on the ultra-high throughput automatic synthesis platform, the company independently built a standardized chemical reaction database and gradually established an accurate and practical AI chemical reaction prediction model tool. At present, relying on the self-built ultra-high throughput automatic synthesis platform, standardized reaction database, AI chemical reaction prediction platform and other characteristic technologies, the company has created a series of high-end technical services such as characteristic molecular block library, reaction condition screening, process optimization, and compound (library) synthesis.

Chengdu Lead is committed to building a high-quality, efficient and innovative molecular discovery and optimization platform, and has established a new drug discovery and optimization platform with DNA coding compound library (DEL), molecular fragment and structure design (FBDD/SBDD), nucleic acid drug design and optimization (STO), and targeted protein degradation (TPD) as the core technologies. Through this cooperation, Chengdu Lead deepens its layout in the field of automated high-throughput chemical synthesis technology and artificial intelligence technology, continuously improves the company's capabilities in molecular discovery and optimization, and accelerates the development of innovative drug projects.

Dr. Jin Li, Chairman and Chief Executive Officer of Lead Chengdu, said: "AIChemEco is a highly innovative company that is able to efficiently complete the conditional screening of organic chemical reactions and the construction of compound libraries through its automated and intelligent synthesis technology. The cooperation will give full play to the advantages of both parties, effectively combining Chengdu's leading molecular discovery and optimization capabilities with the future automated high-throughput chemical synthesis capabilities of Bewise, to accelerate the development of innovative drugs. We look forward to continued and in-depth cooperation between our teams in the future."

Dr. Liao Kuangbiao, Founder of AIChemEco, said: "Chengdu Lead is very good at applying innovative chemical technology to drug development, and its DEL technology is a global leader. We are very pleased to become a strategic partner with Chengdu Lead, and we are very grateful for this trust and trust! As a pioneer and executor of automatic and intelligent synthesis technology, we have developed a series of efficient and practical automatic and intelligent synthesis tools on the basis of characteristic technologies such as automated high-throughput, database and artificial intelligence, and are committed to providing first-class chemical synthesis services for domestic and foreign biomedical enterprises."

【 About Chengdu Lead 】

Chengdu Lead Drug Development Co., LTD. (Shanghai Stock Exchange: 688222.SH, Stock name: Chengdu Lead) is committed to building a world-class innovative biomedical enterprise, headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA.

The company focuses on the discovery and optimization of small molecule and nucleic acid new drugs, We have made efforts to build four core technology platforms: DNA coding compound library technology (including the design, synthesis, screening and expansion application of DEL library), drug design technology based on molecular fragments and three-dimensional structure information (FBDD/SBDD), oligonucleic acid new drug development platform related technology (STO), targeted protein degradation platform related technology (TPD). Through a diversified business model of new drug research and development services, transfer of research projects at different stages and long-term drug listing, Chengdu Lead has established cooperation with hundreds of pharmaceutical companies, biotechnology companies, chemical companies, foundations and scientific research institutions around the world. At present, the company has a number of internal new drug projects in different clinical and preclinical stages.